Talis Biomedical CORP
Market Movers (8-K)
Talis Biomedical Corporation has agreed to terminate its Chicago office lease, resulting in a one-time payment of approximately $3.6 million.
Worse than expected
Talis Biomedical Corporation has reached a settlement agreement with Kriya Therapeutics, resolving a sublease dispute for $1.9 million and dismissing all related lawsuits.
Talis Biomedical Corporation has amended its previous 8-K filing to clarify that only the company and certain of its current and former directors and officers are defendants in a class action lawsuit settlement, not the underwriters of its IPO.
Worse than expected
8-K: Talis Biomedical Reaches $32.5 Million Settlement in Class Action Lawsuit, Plans Chapter 11 Filing
Talis Biomedical Corporation has agreed to a $32.5 million settlement to resolve a securities class action lawsuit, and plans to file for Chapter 11 bankruptcy to implement the settlement.
Worse than expected
Talis Biomedical Corporation will be delisted from the Nasdaq Stock Market after suspending all research and development activities and receiving a notice from Nasdaq that it is considered a public shell.
Worse than expected
Talis Biomedical Corporation has appointed two new independent directors, formed a special restructuring committee, and initiated steps towards a potential Chapter 11 bankruptcy filing.
Worse than expected
Quarterly Earnings (10-Q)
10-Q: Talis Biomedical Corporation Signals Imminent Bankruptcy Filing After Strategic Alternatives Fail
Talis Biomedical Corporation is preparing to file for Chapter 11 bankruptcy after failing to find a viable strategic alternative and ceasing all research and development activities.
Worse than expected
10-Q: Talis Biomedical Reports Q1 2024 Results, Continues Strategic Review Amidst Cost-Cutting Measures
Talis Biomedical Corporation reports a net loss of $13.0 million for Q1 2024 and continues to explore strategic alternatives while significantly reducing operating expenses.
Delay expected
Worse than expected
Annual Reports (10-K)
Talis Biomedical Corporation has ceased most research and development activities and is exploring strategic alternatives, including a potential sale or liquidation, due to operational challenges and market volatility.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
Director Leonard Braden Michael reports acquisition of Talis Biomedical Corp shares through BML Investment Partners, L.P.
Director Leonard Braden Michael reports acquiring 500 shares of Talis Biomedical Corp common stock at $4 per share on September 3, 2024.
Director Leonard Braden Michael reports purchasing 151 shares of Talis Biomedical Corp at $4.25 on August 30, 2024, increasing his indirect holdings.
Director Leonard Braden Michael reports acquisition of Talis Biomedical Corp shares through BML Investment Partners, L.P.